written on 01.04.2014

Gilead's Sovaldi triumph puts major hurt on payers' bottom lines


Hepatitis C wonder-drug Sovaldi is still selling at breakneck pace. And at this rate, it could break some insurers. At $84,000 per 12-week treatment course, Sovaldi's quick uptake is threatening payers' earnings, analysts say–and the drug's stellar efficacy profile leaves them with few options.